These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 15755287)
1. Use of 18F-FDG positron emission tomography following allogeneic transplantation to guide adoptive immunotherapy with donor lymphocyte infusions. Hart DP; Avivi I; Thomson KJ; Peggs KS; Morris EC; Goldstone AH; Linch DC; Ell PJ; Bomanji JB; Mackinnon S Br J Haematol; 2005 Mar; 128(6):824-9. PubMed ID: 15755287 [TBL] [Abstract][Full Text] [Related]
2. Conventional allogeneic hematopoietic stem cell transplantation for lymphoma may overcome the poor prognosis associated with a positive FDG-PET scan before transplantation. Yoshimi A; Izutsu K; Takahashi M; Kako S; Oshima K; Kanda Y; Motokura T; Chiba S; Momose T; Ohtomo K; Kurokawa M Am J Hematol; 2008 Jun; 83(6):477-81. PubMed ID: 18266206 [TBL] [Abstract][Full Text] [Related]
3. Role of whole body positron emission tomography/computed tomography scan with 18F-fluorodeoxyglucose in patients with biopsy proven tumor metastases from unknown primary site. Pelosi E; Pennone M; Deandreis D; Douroukas A; Mancini M; Bisi G Q J Nucl Med Mol Imaging; 2006 Mar; 50(1):15-22. PubMed ID: 16557200 [TBL] [Abstract][Full Text] [Related]
4. F-18 FDG PET/CT in the management of thyroid cancer. Iagaru A; Kalinyak JE; McDougall IR Clin Nucl Med; 2007 Sep; 32(9):690-5. PubMed ID: 17710020 [TBL] [Abstract][Full Text] [Related]
5. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. De Giorgi U; Valero V; Rohren E; Dawood S; Ueno NT; Miller MC; Doyle GV; Jackson S; Andreopoulou E; Handy BC; Reuben JM; Fritsche HA; Macapinlac HA; Hortobagyi GN; Cristofanilli M J Clin Oncol; 2009 Jul; 27(20):3303-11. PubMed ID: 19451443 [TBL] [Abstract][Full Text] [Related]
6. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas. Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094 [TBL] [Abstract][Full Text] [Related]
7. Increased (18)F-fluorodeoxyglucose uptake in benign, nonphysiologic lesions found on whole-body positron emission tomography/computed tomography (PET/CT): accumulated data from four years of experience with PET/CT. Metser U; Even-Sapir E Semin Nucl Med; 2007 May; 37(3):206-22. PubMed ID: 17418153 [TBL] [Abstract][Full Text] [Related]
8. Fever of unknown origin: the role of 18F-FDG PET/CT. Keidar Z; Gurman-Balbir A; Gaitini D; Israel O J Nucl Med; 2008 Dec; 49(12):1980-5. PubMed ID: 18997040 [TBL] [Abstract][Full Text] [Related]
9. [The role of whole body 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in the management of unknown primary tumors]. Wu ZJ; Zhang YX; Wei H; Jia Q Zhonghua Yi Xue Za Zhi; 2007 Aug; 87(32):2253-6. PubMed ID: 18001544 [TBL] [Abstract][Full Text] [Related]
10. Fusion of metabolic function and morphology: sequential [18F]fluorodeoxyglucose positron-emission tomography/computed tomography studies yield new insights into the natural history of bone metastases in breast cancer. Du Y; Cullum I; Illidge TM; Ell PJ J Clin Oncol; 2007 Aug; 25(23):3440-7. PubMed ID: 17592153 [TBL] [Abstract][Full Text] [Related]
11. Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation. Salvatore B; Paone G; Klain M; Storto G; Nicolai E; D'Amico D; Della Morte AM; Pace L; Salvatore M Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):2-8. PubMed ID: 17538522 [TBL] [Abstract][Full Text] [Related]
12. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography and computed tomography in patients with melanoma with palpable lymph node metastases: diagnostic accuracy and impact on treatment. Bastiaannet E; Wobbes T; Hoekstra OS; van der Jagt EJ; Brouwers AH; Koelemij R; de Klerk JM; Oyen WJ; Meijer S; Hoekstra HJ J Clin Oncol; 2009 Oct; 27(28):4774-80. PubMed ID: 19720925 [TBL] [Abstract][Full Text] [Related]
13. 18F-FDG positron emission tomography CT (FDG PET-CT) in the management of pancreatic cancer: initial experience in 12 patients. Saif MW; Cornfeld D; Modarresifar H; Ojha B J Gastrointestin Liver Dis; 2008 Jun; 17(2):173-8. PubMed ID: 18568138 [TBL] [Abstract][Full Text] [Related]
14. Utility of FDG-PET/CT in follow-up of children treated for Hodgkin and non-Hodgkin lymphoma. Rhodes MM; Delbeke D; Whitlock JA; Martin W; Kuttesch JF; Frangoul HA; Shankar S J Pediatr Hematol Oncol; 2006 May; 28(5):300-6. PubMed ID: 16772881 [TBL] [Abstract][Full Text] [Related]
15. Early post-transplantation positron emission tomography in patients with Hodgkin lymphoma is an independent prognostic factor with an impact on overall survival. Sucak GT; Özkurt ZN; Suyani E; Yaşar DG; Akdemir ÖÜ; Aki Z; Yeğin ZA; Yağci M; Kapucu ÖL Ann Hematol; 2011 Nov; 90(11):1329-36. PubMed ID: 21437590 [TBL] [Abstract][Full Text] [Related]
16. FDG-PET in the clinical management of Hodgkin lymphoma. Hutchings M; Eigtved AI; Specht L Crit Rev Oncol Hematol; 2004 Oct; 52(1):19-32. PubMed ID: 15363464 [TBL] [Abstract][Full Text] [Related]